Are MITT, ARX, HHS, FULC Obtaining Fair Deals for their Shareholders?

Investor-rights firm Halper Sadeh LLC says it is investigating potential securities-law and fiduciary-duty violations tied to multiple deals, including Accelerant Holdings’ sale to Thoma Bravo at $20.25/share in cash and Harte Hanks’ sale offering $5.00/share cash or 0.50 shares of Star Equity’s 10% preferred stock. The firm alleges transaction terms may limit superior competing bids and may seek increased consideration and additional disclosures on behalf of shareholders. Expected ownership outcomes cited include TPG Mortgage shareholders owning ~73% of the combined company and Fulcrum shareholders owning ~5.0% post-merger.

Analysis

This is mostly a legal-overhang event, not a fundamental reset. The mechanism is spread widening and time value decay: once a deal is labeled as potentially contestable, arb capital demands a higher return, which hurts smaller, less liquid names first and can persist for weeks even if the claims are boilerplate.

Cash sponsor exits are usually the least vulnerable because litigation rarely changes economics absent a financing or process defect. The more fragile situations are mixed-consideration or stock-for-stock deals, where any delay forces the market to re-mark the consideration against rate moves, sector beta, and financing conditions; that makes the smaller leg the likely underperformer if the news flow turns substantive.

Contrarian view: the market often dismisses these notices as noise, but the real optionality is on process leakage, not headline settlement. The clearest pressure point is any transaction using hard-to-value non-cash paper, where a discount in the instrument can translate into a meaningful economic haircut and force a re-trade over the next 1-3 months; if filings stay generic, the move should fade quickly and there is little reason to own litigation gamma.

Key Decisions for Investors

• ARX: only buy on any post-headline spread widening; this is a low-break-risk cash deal where the edge is spread capture, not a rerating. Risk/reward is favorable if the market overreacts, but cut exposure if the court docket evolves from disclosure noise into process or financing allegations.
• HHS/STRR: favor a relative-value short STRR vs long HHS only if the market prices the preferred-stock consideration as cash-equivalent. The thesis is that illiquidity haircut and valuation uncertainty will get forced into the paper over 1-3 months; cover if the deal is reworked toward more cash or if the spread tightens materially after supplemental disclosures.
• MITT/CHMI: stay neutral until exchange mechanics and closing timing are cleaner. If one leg dislocates, trade the relative value rather than outright REIT beta, because rate volatility can swamp legal alpha and reverse the move quickly.
• FULC: avoid initiating new risk unless the merger spread widens enough to compensate for timing risk. Biotech stock-for-stock deals often deliver poor options R/R unless there is a specific re-pricing catalyst; a flat or slightly lower stock is more likely than a meaningful bump if the legal process stays procedural.